Do you want to read an article? Please log in or register.
Neuropsychiatric adverse effects following switch to vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: early experience from a regional centre
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 2-5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study
Lancet Respir Med
Rayment JH, Davies G, Gaffin JM, Hoppe JE, Kasi AS, Mall MA, McKone EF, Ramsey B, Taylor JL, Tullis E, McDougall E, Pottackal R, Zahigian R, Krone K, Jennings M, Chmiel JF, 121-105 Study Group
doi: 10.1016/S2213-2600(26)00257-2
Pulmonary Fibrosis
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor
J Cyst Fibros
Wainwright CE, Thorat T, Conner S, Quon BS, Duckers J, Lou Y, Mo C, Xue Y, Zhu L, McGarry L
doi: 10.1016/j.jcf.2025.11.014
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
Pulmonary Fibrosis
Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
Br J Clin Pharmacol
Magnas P, Bouazza N, Foissac F, Urien S, Froelicher-Bournaud L, Lui G, Guillemart V, Carlier N, Da Silva J, Fesenbeckh J, Kanaan R, Honoré I, Martin C, Treluyer JM, Tsatsaris V, Burgel PR, Benaboud S
doi: 10.1002/bcp.70620
RECOMMENDED
Pulmonary Fibrosis
Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
J Cyst Fibros
Bardin E, Salvator H, Roquencourt C, Lamy E, Hunzinger N, Sermet-Gaudelus I, De Miranda S, Grenet D, Devillier P, Grassin-Delyle S
doi: 10.1016/j.jcf.2026.06.013
Pulmonary Fibrosis
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M
doi: 10.3390/jcm15072699
RECOMMENDED
Pulmonary Fibrosis
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Kharraz R, Tullis E, Sykes J, Ma X, Sandhu A, Gryz Z, Shulman Y, Tam J, Love A, Ratjen F, Rayment JH, Quon BS, Stephenson AL
doi: 10.1016/j.rmed.2026.108827
RECOMMENDED
Pulmonary Fibrosis
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Chmiel JF, McBennett K, Quon BS, Colombo C, De Wachter E, Fajac I, Mondejar-Lopez P, Polineni D, Robinson P, Sutharsan S, Mall MA, McKone EF, Ramsey B, Taylor-Cousar JL, Tullis E, Suresh NE, Zhang Y, Sosnay P, Jennings M, Barry PJ, 445-110 study group
doi: 10.1093/annalsats/aaoag053
Pulmonary Fibrosis
Medication adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis on the French cystic fibrosis population from 2012-2020
Respir Med
Eid E, Payet C, Fernandez V, Belhassen M, Bessou A, Durieu I, Reynaud Q, Viprey M, French Cystic Fibrosis Centers Network, Cinthia R, Françoise T, Marie-Laure D, Bénédicte RT, Stéphanie B, Julie M, Murie L, Sylvie M, Ralph E, Frédéric H, Manuela S, Laurent M, Rébecca H, Catherine L, Camille A, Nathalie WD, Jane L, Philippe R, Jean-Christophe D, Martine RG, Raphaël C, Aurélie T, Anne G, Isabelle DB, Tiphaine B, Sylvie L, Pierre-Régis B, Isabelle S, Véronique H, Harriet C, Katia BK, Chantal B, Eric D, Sophie R, Christophe M, Nathalie A, Caroline P, Benjamin RP, Laurence W, Dominique G, Léa R, Marlène ME, Julie M, Laure C, Baptiste A, Gabsi Asma
doi: 10.1016/j.rmed.2026.108857